Abstract:Abstract Tumor-associated macrophages (TAMs) are the predominant immune cells within the tumor microenvironment (TME), and their phenotypic modulation is influenced by environmental cues in the TME. In early tumors, TAMs adopt a pro-inflammatory M1-like phenotype, characterized by the secretion of immunogenic cytokines and the ability to kill cancer cells, thus opposing tumorigenesis. However, as tumors progress, TAMs mainly transition to an anti-inflammatory M2-like phenotype, promoting angiogenesis, suppressing anti-tumor immunity, and supporting metastasis. Importantly, a high M2-like/M1-like TAM ratio correlates with poor survival and decreased treatment responses.Despite the significance of TAMs, the molecular mechanisms driving their pro-tumorigenic M2-like phenotype remain unclear. One potential mechanism is metabolic reprogramming, where, traditionally, M1 macrophages favor glycolysis, and M2 macrophages rely on oxidative phosphorylation. However, this paradigm is primarily derived from in vitro experiments using well-defined polarization cocktails, which may not accurately replicate the complex TME. For instance, while in in vitro experiments IL4 and IL13 can induce oxidative phosphorylation and an M2-like phenotype, these cytokines do not seem essential for M2-like TAM polarization in vivo.Our studies reveal that, relative to M1-like TAMs, M2-like TAMs exhibit heightened glycolysis, intracellular lactate accumulation, and increased histone lysine lactylation - an epigenetic mark directly stimulated by lactate. Importantly, we demonstrate that TAM glycolysis and the M2-like phenotype are positively associated with hypoxia within a single tumor (GEM model and human tumors) and across various tumor types (syngeneic models). Inhibition of glycolysis-stimulated lactate production in TAMs through myeloid cell-specific deletion of lactate dehydrogenase A (mLdha-/-) reduces the M2-like:M1-like TAM ratio. This intervention increases tumor-infiltrating CD8+ T cells and reduces tumor growth in pre-clinical models, particularly in highly hypoxic environments. Moreover, to exclude the role of cancer cell-derived lactate on TAMs’ phenotypic changes, we reduced glycolysis in cancer cells by deleting pyruvate kinase muscle isozyme M2 (PKM2). This resulted in decreased lactate production and suppressed tumor growth. However, the M2/M1 ratio remained unaffected, suggesting that the intrinsic lactate production by TAMs is crucial for their phenotype modulation.Our findings underscore the pivotal role of hypoxia-induced glycolysis and lactate production in TAMs, shaping their M2-like phenotype and impacting tumor progression. This understanding not only advances our knowledge of macrophage metabolism and phenotype dynamics in the context of cancer but also in other diseases. Citation Format: Katarzyna Kurylowicz, Kasturi Chakraborty, Chang Cui, Gustavo Gastão Davanzo, Guolin Zhou, Xu Anna Tang, Kelly Q. Schoenfelt, Natalie Pulliam, Catherine A. Reardon, Swati Kulkarni, Tomas Vaisar, Pedro M. Moraes-Vieira, Yingming Zhao, Lev Becker. Glycolysis-stimulated lactate production by tumor-associated macrophages promotes their M2-like phenotype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2686.

The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation

Therapeutic Effect of Melittin-dKLA Targeting Tumor-Associated Macrophages in Melanoma

Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment

Abstract 159: LYVE-1-expressing macrophages modulate the hyaluronan-containing extracellular matrix in the mammary stroma and contribute to mammary tumor growth

Loss of SHP-2 Activity in CD4+ T Cells Promotes Melanoma Progression and Metastasis

Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma

Abstract PO4-25-05: LYVE-1 expressing macrophages modulate the extracellular matrix and contribute to mammary tumor growth

570 Blockade of the Inhibitory Collagen Receptor LAIR-1, PD-L1, and TGF-β Promotes Anti-Tumor Activity Through T Cell Activation and Myeloid Cell Polarization

Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusion

Abstract 1503: Melanoma-derived lymphatic extracellular vesicles suppress dendritic cell differentiation and maturation in the sentinel lymph node

Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis

Targeting tumor-associated macrophages as a novel strategy against breast cancer

862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy

Proliferating macrophages in human tumours show characteristics of monocytes responding to myelopoietic growth factors

Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions

Modulation of macrophage antitumor potential by apoptotic lymphoma cells

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin

Abstract 2686: Glycolysis-stimulated lactate production by tumor-associated macrophages promotes their M2-like phenotype

TIM-3 shuttled by MV3 cells-secreted exosomes inhibits CD4+ T cell immune function and induces macrophage M2 polarization to promote the growth and metastasis of melanoma cells